We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Filter results
You can narrow down the results using the filters
Search
101 result(s) found, displaying 51 to 75
- GuidanceGuidance note 1: Testing of cannabis, cannabis resin and products manufactured from cannabis and cannabis resinGuidance note for 'Testing of cannabis and cannabis resin' updated.
- LegislationNarcotic Drugs Amendment (Medicinal Cannabis) Regulations 2021The Narcotic Drugs Amendment (Medicinal Cannabis) Regulations 2021 introduced a requirement for a review of the medicinal cannabis scheme to be undertaken.
- PublicationsAustralian Government response to the Senate Legal and Constitutional Affairs Committee report: Inquiry into the Regulator of Medicinal Cannabis Bill 2014Response to the report on the inquiry into the RMC Bill
- PublicationsAustralian Government response to the Senate Community Affairs References Committee report: Inquiry into Current barriers to patient access to medicinal cannabis in AustraliaThe Australian Government response to the Inquiry into current barriers to patient access to medicinal cannabis has now been published.
- PublicationsConsultation paper: Kava pilot phase 2: Allowing the commercial importation of kavaOn 11 October 2019, the Prime Minister, the Hon Scott Morrison MP, announced that the Australian Government is stepping up its commitment to the Pacific by launching the kava pilot program (pilot). The pilot involves the relaxation of kava related prohibited import regulations to allow Australians more access to kava and its benefits.
- PresentationsPresentation: Kava pilot phase 2 design (easing the restrictions on the commercial importation of kava)Presentation slides from the Kava pilot phase 2 design webinar on 4 November 2020.
- GuidelinesGuideline: Security of medicinal cannabisGuideline to assist licence applicants and holders in designing and meeting security standards that are required for the cultivation, production and manufacture of medicinal cannabis.
- PublicationsCost Recovery Implementation Statement (CRIS): Regulation of medicinal cannabis, March 2020Information on how the Office of Drug Control implements cost recovery for regulatory activities associated with the direct costs of processing licence and permit applications for the cultivation of medicinal cannabis and the ongoing monitoring and compliance of the regulatory scheme.
- Application formsForm: Informed consentThis form authorises the Office of Drug Control (Department of Health and Aged Care) to obtain information on an individual named in an application for the grant or variation of a licence under the Narcotic Drugs Act 1967.
- PublicationsIndustry consultation paper: Medicinal cannabis cost recovery frameworkA comprehensive review of the Medicinal Cannabis Cost Recovery Framework was undertaken in
late 2019 and early 2020. This paper presents the findings of that review. - PublicationsConsultation paper: Single licence modelThe Government is inviting feedback on the proposal to implement a single medicinal cannabis licence under the Narcotic Drugs Act 1967 and other associated reforms to the licence application process.
- PublicationsHealth Products Regulation Group (HRPG) Regulatory Science Strategy, 2020-2025Our plan for how HPRG will maintain and build its regulatory science capability over the next 5 years.
- PublicationsExample follow-up questions for medicinal cannabis licence applicationsExample follow-up questions to assist applicants in preparing their medicinal cannabis licence applications.
- GuidelinesGuideline: Fit and proper persons and suitable staffGuideline to assist licence applicants and holders to assess whether they are fit and proper to hold a licence to cultivate, produce or manufacture medicinal cannabis and products.
- GuidelinesGuideline: Record keeping and reportingGuideline to assist licence applicants and holders in designing and meeting standards required for record keeping and reporting matters related to cultivation, production and manufacture of medicinal cannabis.
- Application formsApplication form: Licence to export narcotic, psychotropic and precursor substancesApplication form for a licence to export narcotic, psychotropic and precursor substances.
- Application formsApplication form: Permit to export narcotic, psychotropic and precursor substances from AustraliaInformation for applicants who intend to apply for a permit to export narcotic, psychotropic and precursor substances from Australia.
- PublicationsReview of the Narcotic Drugs Act 1967- Final report (2019)Review of the Narcotic Drugs Act 1967 - Final report authored by Professor John McMillan AO, published on 10 July 2019.
- PublicationsCost Recovery Implementation Statement (CRIS): Regulation of medicinal cannabis, November 2018Information on how the Office of Drug Control implements cost recovery for regulatory activities.
- PublicationsConsultation submissions: Kava pilot phase 1A total of 50 submissions were received in response to the public consultation between 22 Feb to 22 March 2019. Read the published submissions.
- PublicationsDiscussion paper: Review of the Narcotic Drugs Act 1967The 2016 amendments to the ND Act included a requirement in section 26A that the Minister cause a review of the operation of the Act to be undertaken as soon as possible after the second anniversary of the commencement of the 2016 amendments.
- PublicationsConsultation paper: Pilot Program to ease restrictions on the importation of kava for personal useThe Australian Government is exploring the appropriate mechanism to increase the quantity of kava that may be imported into Australia by incoming passengers for personal use.
- GuidanceGuidance note: Sponsored import and supply of unregistered medicinal cannabis products – Customs (Prohibited Imports) Regulations 1956Update to guidance on sponsored import and supply of unregistered medicinal cannabis products.
- GuidanceGuidance: Export of medicinal cannabisGuidance on export of medicinal cannabis and products.
- GuidanceGuidance note 2: Obtaining cannabis genetic material from international sourcesPolicy Circular #03/17